Physicians' Academy for Cardiovascular Education

The case for early management

Slides (presentation) - May 7, 2011

The Case for early Management &
prolonged glycemic control

Professor Guntram Schernthaner
Head of the Department of Medicine I
Rudolfstiftung Hospital, Vienna, Austria
CDMC - Munich, May 2011

 


Click on slides to view presentation


RAS blockade in the real world: Clinical lessons from recent trials
Age-adjusted Percentage of U.S. Adults who were Obese or who Had Diagnosed Diabetes
Absolute Numbers of Cases with Diabetes among Chinese Adults (>20yrs of Age) according to Urban or Rural Residence
Age-Specific Prevalence of Diabetes among Chinese Adults 20 Years of Age or Older
Prevalence of Diabetes and Prediabetes in Relation to Body Mass Index in the Chinese Population
Hazards of Prediabetes
Lifestyle Intervention in Prediabetes
Slide 8
Slide 9
Actos Now for Prevention of Diabetes (ACT NOW)
ACT NOW: Time to Occurrence of Diabetes (Kaplan Meier)
Effects of Pioglitazone as compared with Placebo
Factors contributing to cardiometabolic risk
Goals for intensive multifactorial Management for CVD Prevention in Patients with Diabetes
Drug treatment: Stepwise and target driven (Steno 2 Study)
STENO 2: Changes in Risk factors during the follow-up of 8 years in the intensive versus conventionally treated type 2 diabetic patients
The cumulative incidence of the risk of death from any cause (the study’s primary end point) during the 13.3-year study period
New Evidence shows that a Legacy Effect („Metabolic Memory“) of Intensive Glucose Control is relevant for a significant Reduction of CVD Events & CVD Mortality after Long-term follow-up (10-18 years)
DCCT: Intensive therapy significantly reduces and maintains HbA1c
Cumulative Incidence of the first of any of the first Occurrence of Nonfatal Mycardial Infarction, Stroke, or Death from CVD
Clinical Characteristics and Effects of Intensive Glucose Lowering on Primary Cardiovascular (CVD) Endpoint, Total Mortality, & CV Mortality in ACCORD, ADVANCE & VADT
Hypoglycemia Medical Assistance
Mortality in ACCORD (5 year-Data)
ACCORD: Adjusted cause of death in relation to treatment strategy and by occurence of hypoglycemia
CVD Mortality in ACCORD versus ADVANCE
The epidemiological and interventional relationships of cholesterol, blood pressure and HbA1c with cardiovascular disease
Adjusted Hazard Ratios for All-cause Mortality by HbA1c Deciles With Oral Combination & Insulin-based Therapies
Glycemic Control, Complications, and Death in Older Diabetic Patients
Mortality of Patients with Type 2 Diabetes in the Kaiser-Permanente Cohort in Relation to HbA1c (adjusted Hazard Ratios)
Any Complications or Death of Patients with Type 2 Diabetes in the Kaiser-Permanente Cohort in Relation to HbA1c (adjusted Hazard Ratios)
Is the ADA/EASD algorithm for the management of type 2 diabetes based on evidence or opinion? A critical analysis
ADA-EASD „Consensus“ : Expected HbA1c decrease (%) for well-validated and less validated core therapies
ADA and EASD: Decrease in HbA1c .... fact or fiction ?
Durability of Glycemic Control with Thiazlidinediones
No Durability of Glycemic Control with Sulfonylureas

Download presentation

Share this page with your colleagues and friends: